Department of Defense Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of Defense (DoD) is required by law (10 U.S.C. 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: May 2024: The following drug classes/subclass will be reviewed:

a. Insulins Subclass: Basal
Basaglar Kwikpen U-100
Basaglar Tempo Pen U-100
Insulin Degludec
Insulin Degludec Pen (U-100)
Insulin Degludec Pen (U-200)
Insulin Glargine
Insulin Glargine Solostar
Insulin Glargine-YFGN
Lantus
Lantus Solostar
Levemir
Levemir Flexpen
Levemir Flextouch
Rezvoglar Kwikpen
Semglee
Semglee (YFGN)
Semglee (YFGN) Pen
Semglee Pen
Toujeo Max Solostar
Toujeo Solostar
Tresiba
Tresiba Flextouch U-100
Tresiba Flextouch U-200

b. Insulins Subclass: Rapid-Acting Agents
Admelog
Admelog Solostar
Afrezza
Apidra
Apidra Solostar
Fiasp
Fiasp Flextouch
Fiasp Penfill
Humalog
Humalog Junior Kiwkpen
Humalog Kwikpen U-100
Humalog Kwikpen U-200
Humalog Tempo Pen U-100
Humulin R
Insulin Aspart
Insulin Aspart Flexpen
Insulin Aspart Penfill
Insulin Lispro
Insulin Lispro Junior Kwikpen
Insulin Lispro Kwikpen U-100
Lyumjev
Lyumkev Kwikpen U-100
Lyumjev Kwikpen U-200
Lyumjev Tempo Pen U-100
Novolog
Novolog Flexpen
Novolog Penfill

c. Weight Loss Agents Subclass: NA
Adipex-P
Contrave
Lomaira
Orlistat
Qsymia
Saxenda
Wegovy
Xenical
Zepbound

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9201.

Pre-proposal teleconference is on January 31, 2024, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.